Efficacy and Tolerability of Xalatan in Patients

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Latanoprost; Ophthalmic Solutions; Tetrahydrozoline

Criteria

Inclusion Criteria:

• Patient with ocular hypertension at least 22mg Hg

• Patient must be over 18 years old

Exclusion Criteria:

• None listed in the protocol